ARCHERDX LLC

ArcherDX LLC specializes in advanced molecular diagnostics and biotechnological research, with a focus on developing and deploying next-generation sequencing reagents and analytical platforms for precision oncology and hematologic disease characterization. The company’s core capabilities center on variant detection in myeloid malignancies, clonal hematopoiesis analysis, and inflammation-associated genomic biomarkers, leveraging high-sensitivity NGS technologies such as VariantPlex to identify low-frequency somatic mutations in complex patient samples. Their technical expertise includes assay design for liquid biopsy applications, tumor-informed sequencing workflows, and the integration of analytical instrumentation for clinical-grade genomic data generation, positioning them as a niche provider of research-grade diagnostic tools for translational medicine. ArcherDX maintains a strong relationship with the Department of Health and Human Services, delivering critical research support to agencies like the National Heart, Lung, and Blood Institute. Their work consistently supports NIH-funded investigations into the genetic underpinnings of hematologic disorders, cardiovascular disease, and immune dysregulation, indicating a trusted partnership in advancing molecular epidemiology and precision diagnostics for public health research. The company operates primarily under NAICS 541714, focusing on biotechnology R&D excluding nanobiotechnology, and has also engaged in analytical laboratory instrument manufacturing under NAICS 334516, suggesting vertical integration in both assay development and instrumentation. This dual focus enables ArcherDX to bridge the gap between research tools and clinical-grade diagnostics in oncology and hematology markets. ArcherDX LLC is a small business entity headquartered in San Francisco, California, with no publicly disclosed government certifications. Its geographic and operational footprint is centered on California’s biotech corridor, where it contributes to the national ecosystem of genomic innovation supporting federal health research priorities.